- Relmada Therapeutics, Inc.’s (RLMD) sole clinical asset, oral antidepressant therapy esmethadone, is undergoing two pivotal trials for the treatment of MDD.
- Phase 2 study data demonstrate a rapid onset of action that no other currently approved oral therapy can boast.
- Despite esmethadone’s promise, Axsome Therapeutics (AXSM) has a similar oral candidate (AXS-05) with a novel MOA and August 22nd, 2021 PDUFA date, suggesting an ~18-month head start.
- A full investment analysis is presented in the paragraphs below.
For further details see:
Our First Look At Relmada Therapeutics